Bolt Biotherapeutics, Inc. (BOLT) |
|
1.48 0.03 (2.07%)
|
02-03 15:02 |
|
Open: |
1.45 |
Pre. Close: |
1.45 |
|
High:
|
1.51 |
Low:
|
1.45 |
|
Volume:
|
108,000 |
Market Cap:
|
56(M) |
|
|
|
Technical analysis |
as of: 2023-02-03 2:45:34 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 1.85 One year: 2.16 |
| Support: |
Support1: 1.34 Support2: 1.19 |
| Resistance: |
Resistance1: 1.59 Resistance2: 1.85 |
| Pivot: |
1.47 |
| Moving Average: |
MA(5): 1.46 MA(20): 1.46
MA(100): 1.43  MA(250): 1.94 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 46.3 %D(3): 45.2 |
| RSI: |
RSI(14): 54.6 |
| 52-week: |
High: 3.64 Low: 1.17 |
| Average Vol(K): |
3-Month: 298 (K) 10-Days: 137 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BOLT ] has closed below upper band by 45.1%. Bollinger Bands are 30.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.52 - 1.53 |
1.53 - 1.54 |
|
Low:
|
1.41 - 1.42 |
1.42 - 1.43 |
|
Close:
|
1.43 - 1.45 |
1.45 - 1.46 |
|
Company Description |
|
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California. |
Headline News |
Fri, 03 Feb 2023
[UPDATE] GM Tells Chevy Bolt EV Owner It's “Not Responsible” For Fast Charging At Non-Approved Public Stations - InsideEVs
Fri, 03 Feb 2023
GHANAWEB TV LIVE: Former banker shares experience as Bolt driver, committee sitting continues and more coming up - GhanaWeb
Fri, 03 Feb 2023
Saying Hello to Casper, Our New Chevy Bolt EV - CleanTechnica
Thu, 02 Feb 2023
Chevy Bolt EV Gets Fried By Electrify America Fast Charger In Florida - GM Authority
Wed, 01 Feb 2023
Alleged Usain Bolt Fraudster Asked Him for Loan to Repay Victims - Bloomberg
Wed, 01 Feb 2023
Alleged Usain Bolt Fraudster Asked Him for Loan to Repay Victims - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
38 (M) |
|
% Held by Insiders
|
1.999e+007 (%) |
|
% Held by Institutions
|
6.5 (%) |
|
Shares Short
|
1,760 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-9.479e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
996.5 |
|
Return on Equity (ttm)
|
-20.8 |
|
Qtrly Rev. Growth
|
4.83e+006 |
|
Gross Profit (p.s.)
|
-1.08 |
|
Sales Per Share
|
0.02 |
|
EBITDA (p.s.)
|
-2.19 |
|
Qtrly Earnings Growth
|
-2.7 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-76 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
73.37 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
1.68e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
